Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high200.00 26/03/18
52 week low100.00 15/02/18
52 week change 22.50 (16.98%)
4 week volume2,015,559 25/04/18
price155.00
price date1526923920
close157.50

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Latest NewsMore

Verona Pharma plc : Miscellaneous

Verona Pharma plc: Miscellaneous LONDON, May 09, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will present data from its chronic obstructive pulmonary d...

Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLC

Shore Capital today reaffirms its buy investment rating on Verona Pharma PLC (LON:VRP) and cut its price target to 160...

Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018

Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018 Announced positive top-line data from two Phase 2 clinical trials ahead of schedule Met primary and key secondary endpoints in 403 patient Phase 2b clinical trial for maintenance treatment of COPD Met primary and secondary endpoints in Cystic Fibrosis Pha...

Verona Pharma to Present at Bio€quity Europe 2018

Verona Pharma to Present at Bioquity Europe 2018 LONDON, May 04, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Piers Morgan, Chief Financial Officer...

Verona Pharma plc : Result of AGM

Verona Pharma plc: Result of AGM LONDON, May 03, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)(Nasdaq:VRNA), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all resolutions proposed at the Annual General Meeting (AGM...

Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018

Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018 LONDON, May 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases,...

Verona Pharma chief medical officer Kenneth Newman to leave

Respiratory diseases treatment developer Verona Pharma said chief medical officer Kenneth Newman had resigned, effec...

Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLC

Shore Capital today initiates coverage of Verona Pharma PLC (LON:VRP) with a buy investment rating and price target o...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Latest discussion posts More

  • Re: CEO Interview

    Mol. We must expect CEO to be upbeat but if the product performance is so far above all current competitors then surely upon FDA certification with only 105 mill shares in ...
    23-Apr-2018
    millwallfan
  • CEO Interview

    short interview published 200418 http://www.youtube.com/watch?v=Sid3BGs7EEU mol
    23-Apr-2018
    mol42
  • Re: CMO leaving

    I would have hoped the ceo would issue a statement as human nature will assume the worst case scenario and the market reacted accordingly
    13-Apr-2018
    millwallfan

Users' HoldingsMore

Users who hold Verona Pharma also hold..

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP